Pathophysiology of Thrombosis in Heart Failure
|
|
- Damon Morris
- 5 years ago
- Views:
Transcription
1 Pathophysiology of Thrombosis in Heart Failure Barry M. Massie, M.D. Professor of Medicine University of California, San Francisco Disclosures I received consulting fees from Boehringer Ingelheim, Portola and Takeda concerning potential trials of antithrombotic agents in heart failure patients.
2 Pathophysiology of Thrombosis in Heart Failure Points of Discussion Historical perspective Prothrombotic pathophysiological mechanisms Completed and ongoing modern era trials What heart failure setting and which patients? Does routine antithrombotic therapy make sense?
3 Historical Perspectives of Thromboemboli in HF 1950s: Outcomes appeared better in anticoagulated patients (DCM patients treated with prolonged bed rest, high rates of rheumatic valve disease & AF) 1960s-1970s: Patients anticoagulated based on retrospective analyses & findings of thrombi and thromboembolism on autopsy 1980s-90s: Better understanding of hypercoagulability in HF, role of silent MI, systemic and pulmonary emboli in heart failure outcomes 2000-: Concern about aspirin in HF patients
4 Event Rate (%) Pooled Results of 3 Early Trials of Anticoagulants in HF /527 68/415 Confounded by AF, VHD, activity limitation 47/ /527 0 Deaths Anticoagulation Embolic Events Control Harvey WP, Finch CA. N Engl J Med. 1950;242: Anderson GM, et al. Am Heart J. 1950; Griffith GC, et al. Ann Intern Med. 1952;37:
5 Occult Thromboembolism in HF Autopsy data 50% incidence of thromboembolism in HF IDC patients with 18% vs. 0% thromboemboli without vs. with anticoagulation. 2 37% incidence in IDC. 3 IDC and no cardiac thrombus: 20% incidence of unrecognized cerebral damage associated with cognitive defects. 4 1 Spodick DH, Littmann D. Am J Cardiol 1958;1: Fuster V, et al. Am J Cardiol 1981;47: Roberts WC, et al. Am J Cardiol. 1987;60: Schmidt R, Stroke. 1991;22:
6 Heart Failure is a Pro-Thrombotic State Heart failure is a prothrombotic milieu (Virchow s Triad) Embolic rate is 1-3 per 100 patient-years (mostly stroke) Contribution of thrombosis to outcomes (sudden death, progressive heart failure, occult pulmonary embolus) under-appreciated Post-hoc analyses suggest efficacy of antithrombotic Rx Lip GYH, Gibbs CR et al. J Am Coll Cardiol. 1999;33:
7 Virchow s Triad Predisposing Conditions for Thromboembolism Increased procoagulant factors Hypercoagulable state Virchow s Triad Abnormal blood flow Vessel wall abnormalities Abnormalities in blood constituents VTE Increased markers of endothelial damage and inflammation Endothelial damage/ dysfunction Abnormal blood flow Venous stasis Immobility Low cardiac output
8 Factors Increasing Thrombotic Risk in CHF Stasis Low CO, atrial fibrillation, blood viscosity Neurohormonal activation catecholamines, A-II, inflammation, cytokines Endothelial dysfunction Reduced endothelial responses in CHF and atherosclerosis Elevated markers (endothelin and von Willebrand factor) Hypercoagulable state Activated pro-thrombotic factors (thrombin-antithrombin III complexes, fibrinopeptide A, plasminogen activator inhibitor-1) Increased fibrinolysis (prothrombin F1 2, d-dimers) Increased platelet aggregability (ß-thromboglobulin, PF IV)
9 Platelet function Factors Contributing to Hypercoagulability in HF Increased platelet aggregation and elevated beta thromboglobulin, P selectin, PECAM 1 (platelet/endothelial cell adhesion molecule 1; CD 31), osteonectin Increased coagulability Elevated TNF, thrombin antithrombin complexes (TAT), D-dimer, prothrombin fragment F (even greater increase in AF), fibrinopeptide A, IL 6 (also increased in AF) Garg RK, et al. Prog Cardiovasc Dis. 1998;41: Davis CJ, et al. Int J Cardiol. 2000;75:15-21.
10 Rationale for Antithrombotic Therapy in Chronic HF Prevention of stroke Prevention of systemic & pulmonary embolism Prevention of coronary thrombosis Retarding progression of HF Prevention of venous thromboembolism Prolongation of survival
11 Risk of Stroke in SAVE Low LVEF: For each 5%, risk of stroke RR 18% Older age: For each 5 yr, RR 18% Atrial fibrillation Risk of stroke doubled in men and tripled in women (Framingham) Etiology of heart failure Recent large MI (usually anteroapical) No clear excess risk for DCM, but perhaps for peripartum cardiomyopathy and acute myocarditis Anticoagulation during follow-up: RR 0.19 Aspirin use during follow-up: RR 0.44 Loh, et al. NEJM 1997;336:251
12 Relative Risk of Thromboembolic Events by Gender in SOLVD Dries et al JACC; 1997;29:1074
13 Embolic Rates in CHF and AF Rates per 100 patient-years Trial All Emboli Stroke Death V-HeFT* % SOLVD* % AF trials (all pts) % AF trials (high-risk) 6 17%/y * Includes AF patients (some anticoagulated) Dunkman WB, et al. Circulation. 1993;87 (6 Suppl):VI Dries DL, et al. J Am Coll Cardiol. 1997;29: No authors listed. Arch Intern Med. 1994;154:
14 Cause of Death in Heart Failure Noncardiac 13% Myocardial Infarction 12% Fatal Stroke or PE 3% Sudden Death 23% Pump Failure 49% Dries et al, JACC 1998;32:695
15 ATLAS Effect of Autopsy on Classification of Death Percent Sudden Cardiac Death 171 patients (12.4%) had autopsy No Autopsy CHF MI Autopsy Can these outcomes be prevented with antiplatelet agents or anticoagulation? Uretsky BF, et al. Circulation. 2000;102:
16 Evidence for Embolism in Cardiomyopathy Increased LV end-diastolic volume and diminished contractility cause stasis and thrombus formation. Peripheral embolism in patients with dilated LV is well-documented 12% of patients with cardiomyopathy have LV thrombus (may be selection bias). Low EF is the main risk factor. Chaudhry et al, Circulation 1998;97:412 Kalaria et al, Am Heart J 1998;135:215
17 Relationship Between Mural Thrombus and Systemic Emboli Risk Increased Data confounded by posthoc nature of analyses and use of anticoagulation. Risk Not Increased Katz (n = 264) Cioffi (n = 406) Stratton (n = 83) Natterson (n = 224) Falk (n = 25) Ciaccheri (n = 126) Gottdiener (n = 123) Blondheim (n = 91) Kyrle (n = 38) Mobile and protruding thrombi may be more likely to embolize.
18 Adjusted Hazard Ratios Enalapril vs. Placebo SOLVD Interaction Between Antiplatelet Tx and Enalapril Effect 1.2 All-cause Mortality Interaction P = % 10% 20% 13% 10% 20% All Patients APA Users APA Non-users Al-Khadra AS, et al. J Am Coll Cardiol. 1998;31: Al-Khadra AS, et al. J Am Coll Cardiol. 1998;31:
19 Pathways Affected by ACE-Inhibitors ACE-I Angiotensinogen Angiotensin I - Angiotensin II Renin ACE (Kininase II) ASA - - COX-1 Bradykinin Inactive fragments PGE 2 PGI 2 NOS NO Angiotensin II Receptors ACE-I
20 WASH Study All-cause Hospitalization Percent Excess driven by higher rate of heart failure hospitalizations Months P = 0.05 Control 48 (48%) Warfarin 42 (47%) Aspirin 58 (64%) Cleland JGF. Presented ESC 1999.
21 WATCH: Warfarin and Antiplatelet Trial in CHF Objective: To determine the optimal anti-thrombotic agent for heart failure patients, with regard to clinical outcomes, safety, and cost. Hypotheses: Anticoagulation with warfarin is superior to antiplatelet therapy with aspirin in preventing vascular events in chronic heart failure patients. Comparison of warfarin vs aspirin Aspirin may have an adverse effect in chronic heart failure patients, possibly due to interference with the action of ACE inhibitors. Comparison of clopidogrel vs aspirin
22 WATCH Study Design Recruitment x 3 years 142 sites in US (VA & non-va), Canada, and UK Warfarin (INR ) (open-label) 1,500 patients Aspirin 162 mg/d (double-blind) 1,500 patients Clopidogrel 75 mg/d (double-blind) 1,500 patients Intent-to-treat follow-up for up to 5 y (minimum 2 y) 3-mo. visits; 6 week contacts/inr checks 80 90% power to detect 20% intergroup differences at α = with annual event rates of 14 18%
23 Event Rate Death and Non-fatal MI or Stroke Aspirin (n = 523) Clopidogrel (n = 524) Warfarin (n = 540) W vs A: HR 0.99, CI C vs A: HR 1.10, CI Year of Follow-up Massie B. Circulation 2009;119;
24 Aspirin vs Warfarin Aspirin (523) Warfarin (540) N % N % Death, MI, stroke Death Non-fatal MI Non-fatal stroke Heart failure hospitalization There were no significant differences between aspirin and clopidogrel p
25 Heart Failure Hospitalizations Patients Hospitalized 27%, P = 0.01 P = No. of Hospitalizations/ 100 patient-years 31%, P < P = A C W 0 A C W Aspirin Clopidogrel Warfarin
26 Warfarin vs Aspirin in Reduced Cardiac EF (WARCEF) Ongoing NINDS funded trial of warfarin vs aspirin in HF patients at high risk of stroke. Primary endpoint of death and stroke. Results anticipated early 2012 Prespecified combined analyses with WATCH are included. Together, these studies should provide definitive conclusions to the questions unresolved by WATCH
27 2008 US Guidelines for Antithrombotic Therapy in Chronic HF (AHA/ACC & ACCP) Anticoagulation recommended for heart failure patients: With chronic or paroxysmal AF or flutter (IA, warfarin) With prior systemic or pulmonary embolic events (IIA, warfarin) With recent large anterior MI or LV thrombi (IIA, short term warfarin) At risk for venous thromboembolism in hospitalized patients with risk factors (IA, LMWH or UFH) Anticoagulation possibly beneficial (but unproven) In other patients with ventricular thrombi (IIB) Anticoagulation not recommended In other patients with non-ischemic CM (IB) Aspirin for prevention of vascular events Recommended at mg QD in CAD patients (IC) Warfarin and clopidogrel possible alternatives, IIB) Not recommended in non-ischemic CM (IB)
28 Mechanisms of Current and Investigational Antithrombotic Agents Hirsh J, et al. Circulation 2007;116:551
29 Does a trial of antithrombotic therapy in heart failure patients make sense: WATCH experience? Major sources of arterial thromboembolism (large AMI, LV aneurysm, severe LV dysfunction) have become uncommon. Event rates likely to be impacted by an antithrombotic agent are low (3/100 pt-yrs for stroke + MI; 12/100 pt-years for stroke + MI + death) and do not differ between warfarin and aspirin (but strokes less frequent on warfarin,? AF patients). HF hospitalizations exceed the combined primary endpoint events and were significantly more frequent in the aspirin group, probably reflecting an interaction with ACE inhibitors. Placebo controlled trials that include AF patients would be unethical and an active anticoagulant comparator would be required.
30
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationAnti-Thrombotic Therapy Update 2017 Sophia-Antipolis (France), February European Heart House
Anti-Thrombotic Therapy Update 2017 Sophia-Antipolis (France), February 23-25 2017 European Heart House SESSION 1: PATHOPHYSIOLOGY AND METHODOLOGY Understanding Thrombosis in... February 23 2017 14:10-15:45
More informationControversies in Anticoagulation
Controversies in Anticoagulation Katrina Babilonia, PharmD Pharmacy Clinical Specialist Anticoagulation University of Colorado Hospital Katrina.babilonia@uch.edu Patient Case: DS DS 67 y/o CC: Chest Pain
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationCoagulation and ischaemic stroke
ESC Council on Stroke ESC Heart & Brain Workshop Prague, January 2018 Coagulation and ischaemic stroke Wolfram Doehner, PD, PhD Center for Stroke Research Berlin & Department of Cardiology, Campus Virchow
More informationDANIEL L. DRIES, MD, MPH,* YVES D. ROSENBERG, MD, MPH,* MYRON A. WACLAWIW, PHD, MICHAEL J. DOMANSKI, MD*
1074 JACC Vol. 29, No. 5 Ejection Fraction and Risk of Thromboembolic Events in Patients With Systolic Dysfunction and Sinus Rhythm: Evidence for Gender Differences in the Studies of Left Ventricular Dysfunction
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationControversies in Risk Stratification
Controversies in Risk Stratification Things are not as simple as they seem Banff 2017 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of AF AF burden Paroxysmal? Persistent?
More informationClinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
More informationHemodynamic Disorders, Thrombosis, and Shock. Richard A. McPherson, M.D.
Hemodynamic Disorders, Thrombosis, and Shock Richard A. McPherson, M.D. Edema The accumulation of abnormal amounts of fluid in intercellular spaces of body cavities. Inflammation and release of mediators
More informationWhat are blood clots?
What are blood clots? Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service GP Partner Westcliffe Medical Group Created 5/31/18 Dr. Matthew
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationAntithrombotic therapy for patients with congenital heart disease. George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki
Antithrombotic therapy for patients with congenital heart disease George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki Disclosures Educational fees from Astra Zeneca, GSK Research fees from
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationIs Stroke Frequency Declining?
Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac
More informationThe Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction
The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction Cardiovascular Center, Korea University Guro Hospital 2007. 4. 20 Seung-Woon Rha, MD, PhD Introduction 1.
More informationChanging Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events
Changing Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events Deepak L. Bhatt, MD, MPH Executive Director Interventional Cardiovascular Programs Brigham and Women s Hospital
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationDoes COMPASS Change Practice?
Does COMPASS Change Practice? C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division Chairman, PERFUSE Study Group Founder,
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationVirchow s triad in AF
1- Pathophysiology 2- Atrial Fibrillation Thrombogenesis Prevention (OAC / APA) 3- Thrombogenesis in AF complicating ACS Prevalence Consequences 4- PCI (with stents) PCI and antithrombotic treatment 5-
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationSubclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study Meagan Sullivan, PharmD PGY2 Cardiology Pharmacy Resident University of Chicago Medicine
More informationPRO. HF treatment can reduce the risk of stroke. Wolfram Doehner, PD, PhD
ESC Council on Stroke ESC Heart & Brain Workshop Prague, January 2018 HF treatment can reduce the risk of stroke PRO Wolfram Doehner, PD, PhD Center for Stroke Research Berlin & Department of Cardiology,
More informationCHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationShock, Hemorrhage and Thrombosis
Shock, Hemorrhage and Thrombosis 1 Shock Systemic hypoperfusion due to: Reduction in cardiac output Reduction in effective circulating blood volume Hypotension Impaired tissue perfusion Cellular hypoxia
More informationMedical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece
Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants
More informationStroke and ASA / FO REBUTTAL
REBUTTAL Definition of an ischemic stroke Definition of a PFO Evidence for a causal role of PFO in stroke Evidence against a role of PFO in stroke Stroke recurrencies in stroke (PFO) patients Medical treatment
More informationChallenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest
Challenges in Anticoagulation Bridging and Emerging Therapies Ethan Cumbler MD FACP Associate Professor of Medicine Hospitalist Medicine Section University of Colorado Denver 2011 Disclosures and Relationships
More informationStudy design: multicenter, randomized, open-label trial following a PROBE design
Subgroup Analysis from the RE-DUAL PCI Trial Dual Antithrombotic Therapy with in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Jonas Oldgren, Philippe Gabriel Steg, Stefan
More informationThe Korean Society of Cardiology COI Disclosure
The Korean Society of Cardiology COI Disclosure Name of First Author: Yongwhi Park The authors have no financial conflicts of interest to disclose concerning the presentation 2017 Annual Spring Scientific
More informationAtrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology
Atrial Fibrillation Ivan Anderson, MD RIHVH Cardiology Outline Definition and Pathophysiology Rate versus rhythm control Rate control thresholds (how much is enough) Anti-coagulation CHADS2VASc score HASBLED
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı
ANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı Dr. Sabri DEMİRCAN Ondokuz Mayıs Üniversitesi Tıp Fakültesi Kardiyoloji ABD, Samsun Copyright 2001 Harcourt Canada Ltd.
More informationA Patient with Chest Pain and Atrial Fibrillation
A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationSecondary Stroke Prevention: A Precautionary Tale
Secondary Stroke Prevention: A Precautionary Tale Kirsten George-Phillips, BSP Clinical Practice Leader, AHS Clinical Pharmacist, AHS Owen Stroke Prevention Clinic Learning Objectives! Examine literature
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationPathology of pulmonary vascular disease. Dr.Ashraf Abdelfatah Deyab. Assistant Professor of Pathology Faculty of Medicine Almajma ah University
Pathology of pulmonary vascular disease Dr.Ashraf Abdelfatah Deyab Assistant Professor of Pathology Faculty of Medicine Almajma ah University Pulmonary vascular disease Type of pulmonary circulation: Types
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationSTEMI 2014 YAHYA KIWAN. Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital
STEMI 2014 YAHYA KIWAN Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital Aspiration Thrombectomy Manual aspiration thrombectomy is reasonable for patients undergoing primary PCI. I
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationState of the Art in the ACS Atrial Fibrillation Overlap Syndrome
State of the Art in the ACS Atrial Fibrillation Overlap Syndrome C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationAntithrombotic. DAPT or OAC?
Antithrombotic treatment after TAVI: DAPT or OAC? Striking the right balance. Pascal Vranckx MD, PhD. Hartcentrum Hasselt, Belgium. Disclosure of Interest Pascal Vranckx has the following potential conflicts
More informationT he risk of stroke and thromboembolism is substantially
759 CARDIOVASCULAR MEDICINE Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation G Y H Lip, L A Pearce,
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationIDEAL MANAGEMENT OF PULMONARY EMBOLISM DISCLOSURES
IDEAL MANAGEMENT OF PULMONARY EMBOLISM Samuel Z. Goldhaber, MD Section Head, Vascular Medicine Director, Thrombosis Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine
More informationWHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France.
TAVI WITH ATRIAL FIBRILLATION: WHICH ANTITHROMBOTIC REGIMEN? G. MONTALESCOT (PARIS, FR) Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France www.action-cœur.org Dr. Montalescot
More informationAnticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationThrombosis. Jeffrey Jhang, M.D.
Thrombosis Jeffrey Jhang, M.D. Introduction The human hemostatic system has evolved to maintain blood flow under normal physiologic conditions while remaining primed to rapidly respond to vascular injury
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationAspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission?
Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Ty J. Gluckman, MD, FACC, FAHA Medical Director, Center for Cardiovascular Analytics, Research and Data Science
More informationCHAPTER 28. Heart Failure and Antithrombotics INTRODUCTION EPIDEMIOLOGY. Mrinal Kanti Das
CHAPTER 28 Mrinal Kanti Das Heart Failure and Antithrombotics INTRODUCTION Heart failure is a common and burgeoning problem affect ing 1 2% of the adult population and about 6 10% of them are above 65
More informationHF and CRT: CRT-P versus CRT-D
HF and CRT: CRT-P versus CRT-D Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief, Cardiology Section Philadelphia VA Medical Center Philadelphia, PA
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationPathophysiology. Tutorial 3 Hemodynamic Disorders
Pathophysiology Tutorial 3 Hemodynamic Disorders ILOs Recall different causes of thrombosis. Explain different types of embolism and their predisposing factors. Differentiate between hemorrhage types.
More informationWhich Cyanotic Patient Needs Anticoagulation?
Which Cyanotic Patient Needs Anticoagulation? Erwin Oechslin, MD, FRCPC, FESC Director, Adult Congenital Heart Disease Program The Bitove Family Professor of ACHD Professor of Medicine, U of T Peter Munk
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationShould All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?
Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Avi Shimony, MD, FESC Cardiology Division Soroka University Medical Center Ben-Gurion University, Beer-Sheva Disclosure
More informationDisclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationAnticoagulants and antiplatelet therapy in the older patient: Choosing wisely
Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely Rajiv Gulati, MD PhD Advances in Cardiac Arrhythmias & Great Innovations in Cardiology Torino, October 2015 2015 MFMER 3477310-1
More informationCADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm
CADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm P. Timothy Pollak, MD, PhD University of Calgary Rocky Mountain/ACP Internal Medicine Meeting,
More informationControversies in Risk Stratification
Controversies in Risk Stratification There are more questions than answers So---Let me pose the questions Banff 2016 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of
More informationLow Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationAnticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar
Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for
More informationUpdate on Oral Anticoagulation for Mechanical Heart Valves
Update on Oral Anticoagulation for Mechanical Heart Valves Douglas C. Anderson, Pharm.D., D.Ph. Professor and Chair Dept. of Pharmacy Practice Cedarville University School of Pharmacy OHIO SOCIETY OF HEALTH-SYSTEM
More information